Crossmark

Prevalence of cardiovascular risk factors and disease in patients with schizophrenia: baseline results from a prospective cohort study with long-term clinical follow-up

Crossref DOI link: https://doi.org/10.1038/s41537-025-00642-w

Published Online: 2025-07-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Polcwiartek, Christoffer

Jensen, Svend Eggert

Frøkjær, Jens Brøndum

Nielsen, René Ernst
License Information

Text and Data Mining valid from 2025-07-08

Version of Record valid from 2025-07-08
More Information

Article History

Received: 9 August 2024

Accepted: 19 June 2025

First Online: 8 July 2025

Competing interests

: CP has received speaking fees from Lundbeck and research grant support from the Danish Cardiovascular Academy (grant number: CPD5Y-2021003-DCA), funded by the Novo Nordisk Foundation (grant number: NNF20SA0067242) and the Danish Heart Foundation. REN reported receiving research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials; receiving speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen-Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva A/S, and Eli Lilly; has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda, and Medivir; and being an investigator for Janssen-Cilag, Lundbeck, Boehringer, Compass, and Sage. All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below